Korro Bio (KRRO) Common Equity (2018 - 2026)
Korro Bio's (KRRO) quarterly Common Equity came in at $119.6 million in Q1 2026, down 13.91% YoY from $139.0 million in Q1 2025, and up 132.57% on a QoQ basis from $51.4 million in Q4 2025.
Korro Bio (KRRO) Common Equity (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Common Equity data on file, last reported at $119.6 million in Q1 2026.
- Quarterly Common Equity fell 13.91% year-over-year to $119.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.6 million (down 13.91% YoY) and the FY2025 annual result came in at $51.4 million, down 67.93% from the prior year.
- Common Equity climbed to $119.6 million in Q1 2026, from $51.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $198.1 million in Q2 2024 to a low of -$153.3 million in Q3 2023.
- A 5-year average of $68.7 million and a median of $112.7 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 271.57% in 2023, down 286.96% in 2023.
- Tracing KRRO's Common Equity over 5 years: stood at -$99.0 million in 2022, then soared by 271.57% to $169.9 million in 2023, then declined by 5.59% to $160.4 million in 2024, then slumped by 67.93% to $51.4 million in 2025, then jumped by 132.57% to $119.6 million in 2026.
- The last three Common Equity figures came in at $119.6 million (Q1 2026), $51.4 million (Q4 2025), and $99.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Korro Bio | 229.39 Mn | 114.36 Mn | - | 103.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.23 Mn |
| Mar 31, 2026 | 119.63 Mn |
| Dec 31, 2025 | 51.44 Mn |
| Sep 30, 2025 | 99.03 Mn |
| Jun 30, 2025 | 115.10 Mn |
| Mar 31, 2025 | 138.96 Mn |
| Dec 31, 2024 | 160.42 Mn |
| Sep 30, 2024 | 179.63 Mn |
| Jun 30, 2024 | 198.08 Mn |
| Mar 31, 2024 | 151.36 Mn |
| Dec 31, 2023 | 169.91 Mn |
| Sep 30, 2023 | -153.26 Mn |
| Jun 30, 2023 | -135.40 Mn |
| Mar 31, 2023 | -118.23 Mn |
| Dec 31, 2022 | -99.03 Mn |
| Sep 30, 2022 | 81.97 Mn |
| Jun 30, 2022 | 95.85 Mn |
| Mar 31, 2022 | 112.67 Mn |
| Dec 31, 2021 | -42.21 Mn |
| Sep 30, 2021 | 147.12 Mn |